Verrica Pharmaceuticals' Molluscum Contagiosum Topical Solution Gets FDA Approval
By Denny Jacob
Verrica Pharmaceuticals on Friday said the Food and Drug Administration approved Ycanth topical solution to treat molluscum contagiosum in adults and patients ages two and up.
The dermatology therapeutics company said it plans to make Ycanth available by September.
Molluscum contagiosum is an infection caused by a poxvirus, which can result in a benign, mild skin disease characterized by growths on the body.
Chief Executive Ted White said molluscum contagiosum primarily affects children and is commonly transmitted in households, schools and swimming pools through skin-to-skin contact given its highly contagious nature.
Trading of the company's stock was halted at 3:58 p.m. ET ahead of the news.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
July 21, 2023 16:50 ET (20:50 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
How Anti-Obesity Drugs Are Innovating the Healthcare Market
-
What’s Happening In the Markets This Week
-
Why Immigration Has Boosted Job Gains and the Economy
-
What to Invest in During High Inflation
-
Never Mind Market Efficiency: Are the Markets Sensible?
-
Starbucks Stock Could Use a Pick-Me-Up After Big Selloff; Is it a Buy?
-
5 Cheap Stocks to Buy From an Attractive Part of the Market
-
Markets Brief: All Eyes On Inflation
-
After Earnings, Is Lyft Stock a Buy, a Sell, or Fairly Valued?
-
8 Stock Picks in the Apparel Industry
-
Baidu Earnings: Advertising Weakness Offset by Continued Growth In Cloud Business
-
Going Into Earnings, Is Target Stock a Buy, a Sell, or Fairly Valued?
-
Walmart Earnings: Low Prices and Strong Digital Presence Drive Market Share Gains
-
After Earnings and a Big Selloff, Is Shopify Stock a Buy, a Sell, or Fairly Valued?
-
Cisco Earnings: Positive Guidance and Splunk Inclusion Align With Our Long-Term Thesis
-
3 Warren Buffett Stocks to Buy After Berkshire Hathaway’s Just-Released 13F Filing